Parkinson’s disease (PD) is a common neurodegenerative disease typified by a movement
disorder consisting of bradykinesia, rest tremor, rigidity, and postural instability. Treatment …

Parkinson’s disease (PD) is a neurodegenerative disorder pathologically distinguished by
degeneration of dopaminergic neurons in the substantia nigra pars compacta. Muscle rigidity, …

… The lowest carrier frequency was reported to be 2.3% in Norwegian Parkinson's disease
patients [13]. Notably, there is considerable reduction of penetrance in that only about 10% of …

… Food and Drug Administration approved the drug levodopa … identified 47 trials as PD treatment
drugs or therapies. Among them, … Additionally, we discuss the most potent drug or therapy …

… Our goal is to provide an update of cholinergic systems and changes in Parkinson's disease
and isolated REM sleep behaviour disorder, a Parkinson's disease prodrome. We discuss …

… , the number of patients with Parkinson’s disease in this region is expected to more than
fivefold by 2040, from an estimated 20,000 to 120,000 [15]. Familial Parkinson disease (FPD) is …

… ’s disease and Parkinson’s disease. So far, the findings are exciting and promising. Here,
we delineate the dysfunction of the TFEB-mediated ALP in NDs, and we summarize small …

The most commonly used treatment for Parkinson’s disease (PD) is levodopa, prescribed in
conjunction with carbidopa. Virtually all patients with PD undergo dopamine replacement …

… insights into evidence-based63 as well as emerging and experimental therapeutics of PD. …
. The 200-year journey of Parkinson disease: reflecting on the past and looking towards the …

… in medical history for James Parkinson's by addition of more symptoms to … Parkinson's
disease (PD) for those symptoms [4]. Being the second most familiar ND after Alzheimer's disease …